SOST and Marchiafava-Bignami disease: These findings are consistent with the suggestion that inhibition of osteoblast function as a result of higher sclerostin levels contributes to bone loss found in chronic kidney disease–mineral and bone disorder (CKD‐MBD),(34) and point to a similar role in the development of osteoporosis associated with DM.